Pfizer Inc.
NYSE•PFE
CEO: Dr. Albert Bourla D.V.M., Ph.D.
セクター: Healthcare
業種: Drug Manufacturers - General
上場日: 1972-06-01
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
連絡先情報
時価総額
$151.25B
PER (TTM)
19.5
36
配当利回り
6.5%
52週高値
$27.94
52週安値
$20.92
52週レンジ
順位23Top 9.4%
5.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$17.56B+0.00%
直近4四半期の推移
EPS
-$0.29+0.00%
直近4四半期の推移
フリーCF
$4.50B+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
2025 Financial Performance Summary Total revenues $62.6B, down 2% operationally; Adjusted EPS $3.22, up 4% versus prior year results.
COVID-19 Revenue Contraction Paxlovid revenue dropped 59% operationally; Comirnaty revenue fell 20% operationally, impacting overall financial results.
R&D Savings Reinvestment Plan $500M R&D savings from cost realignment expected to be reinvested in 2026 pipeline development initiatives.
リスク要因
Patent Expiry Revenue Erosion Anticipate significant revenue reduction from patent/exclusivity expiries accelerating between 2026 through 2030.
Pricing and Access Pressures Ongoing IRA mandates and MFN initiatives create greater pricing pressure across key U.S. commercial markets.
Competitive Product Launches New branded generics and biosimilars may erode sales of existing products, impacting market exclusivity.
Supply Chain Vulnerabilities Risks persist from manufacturing disruptions, shortages, and potential regulatory actions impacting global product distribution.
見通し
Strategic Growth Opportunities Focus Capitalizing on pipeline advancement via Metsera, Seagen acquisitions, and new YaoPharma/3SBio in-licensing deals.
Cost Reduction Program Execution Executing $5.7B cost realignment goal and $1.5B manufacturing optimization savings through 2027.
2026 Key Priority Delivery Focus on maximizing transaction value, delivering critical R&D milestones, and scaling AI across the business.
同業比較
売上高 (TTM)
$65.01B
$62.58B
$52.71B
粗利益率 (最新四半期)
92.7%
86.8%
81.9%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| MRK | $285.86B | 15.8 | 36.2% | 36.9% |
| AMGN | $197.41B | 25.6 | 96.7% | 60.3% |
| GILD | $179.99B | 21.2 | 41.0% | 41.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
8.6%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし